Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

May 25, 2021

Additional Efforts Necessary to Implement New Recommended Age Range for Colorectal Cancer Screenings

Author(s):

Jamie Cesanek

In an accompanying editorial to the recently updated U.S. Preventive Services Task Force recommendation for colorectal cancer screenings, doctors suggested additional measures that would help increase the screening rate among eligible adults and potentially lower the mortality rate.

The U.S. Preventive Services Task Force (USPSTF) recently announced an updated recommendation for the screening of colorectal cancer, lowering the age to begin screenings from 50 to 45 and mandating insurance coverage.

But according to an accompanying editorial opinion piece published in JAMA Oncology, further research is still necessary to determine the causes of early-onset colorectal cancer in patients even younger than 45, and additional efforts to reach at-risk groups are necessary to implement these new guidelines.

Most early-onset colorectal cancer deaths occur between ages 45 to 49, said the authors, but data suggests the rate of increase in incidence is steepest in the youngest patients. Colorectal cancer incidence was found to be increasing by 2% per year among 20- to 29-year-olds versus 1.3% among 40- to 49-year-olds.

The authors also noted that implementation of the updated recommendation will be key to achieving prevention of the disease. Data shows that in 2018, the colorectal cancer screening rate in the United States was 68.8%. It was lower among the uninsured, low-income individuals and racial and ethnic minorities, proving that it’s crucial to reach nearly one third of the eligible-for-screening population.

In a change from the 2016 recommendations, the USPSTF conducted modeling studies in groups based on gender and race, finding that screening is equally effective in every population. However, disparities in colorectal cancer incidence and mortality persist and require further attention, according to Dr. Kimmie Ng, the editorial’s first author and director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute.

Black adults are 20% more likely to be diagnosed with colorectal cancer and 40% more likely to die than other groups, according to the American Cancer Society.

“So, we do hope that by lowering the screening recommendation to age 45 for everybody, that more Black Americans will also be getting screened,” said Ng, in an interview with CURE®.

“And hopefully, we're going to be making a dent in eliminating some of these disparities. We do think that the biggest reason for the disparities is unfortunately racial inequities in access to care and access to quality care. And so, we know that Black and Hispanic adults, for example, have a lower uptake of screening. So we really need to focus a lot of our public health efforts and public awareness campaigns in these communities where screening really will have a big impact.”

The editorial authors suggested several potential efforts beyond guidelines, quality metrics and public awareness campaigns that would encourage higher screening rates, such as an employer-provided “wellness day” for employees aged 45 to 75 to undergo screening or to be assisted with fecal immunochemical test (FIT) kits, appointment scheduling and daycare/transportation.

Other suggestions included occupational health services providing on-the-spot FIT screenings bundled with flu shots, health systems offering weekend or after-hours appointments for colonoscopies, safe ride services or the extension of post-procedure recovery periods for patients who lack social support, special efforts to reach vulnerable populations (underinsured, self-employed, mentally ill, disabled or incarcerated patients), physician accountability for prevention and outreach to patient families as well as improved communication from physicians who have diagnosed patients to their patients’ at-risk relatives.

As research continues to examine the causes of the recent rises in colorectal cancer incidence among younger age groups, scientists are considering environmental factors, the rise of obesity and sedentary behavior, according to Ng.

“We don't think that it's any change in the genetic makeup of human beings, because the change happened a little bit too abruptly and quickly, starting in the mid 1990s,” said Ng. “And most of the young people who are being diagnosed actually do not have a genetic syndrome or a family history of colon cancer.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of colorectal cancer
Photo of Dr. Usman Shah
An off-the-shelf cancer vaccine is associated with durable responses and a reduced risk of relapse and death among patients with pancreatic or colorectal cancers.
Related Content
Advertisement
Picture of Dr. Usman Shah
September 13th 2025

Colorectal Cancer Screening Shifts as Cases Rise in Adults Under 50

Spencer Feldman
Teri Greige with medals
September 13th 2025

The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer

Brielle Benyon
The FDA granted breakthrough device designation to an MRD test for patients with stage 2 colorectal cancer: © stock.adobe.com.
September 13th 2025

FDA Grants Breakthrough Device Status to MRD Test in Colorectal Cancer

Alex Biese
‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC
September 13th 2025

‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC

Jamie Cesanek
Image of Dr. with text.
September 13th 2025

Off-The-Shelf Vaccine Elicits Durable Responses in Pancreatic, Colorectal Cancers

Alex Biese
The FDA approved an IND application for ABT-301 in metastatic colorectal cancer: © stock.adobe.com.
September 13th 2025

FDA Approves Application for ABT-301 in Metastatic Colorectal Cancer

Alex Biese
Related Content
Advertisement
Picture of Dr. Usman Shah
September 13th 2025

Colorectal Cancer Screening Shifts as Cases Rise in Adults Under 50

Spencer Feldman
Teri Greige with medals
September 13th 2025

The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer

Brielle Benyon
The FDA granted breakthrough device designation to an MRD test for patients with stage 2 colorectal cancer: © stock.adobe.com.
September 13th 2025

FDA Grants Breakthrough Device Status to MRD Test in Colorectal Cancer

Alex Biese
‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC
September 13th 2025

‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC

Jamie Cesanek
Image of Dr. with text.
September 13th 2025

Off-The-Shelf Vaccine Elicits Durable Responses in Pancreatic, Colorectal Cancers

Alex Biese
The FDA approved an IND application for ABT-301 in metastatic colorectal cancer: © stock.adobe.com.
September 13th 2025

FDA Approves Application for ABT-301 in Metastatic Colorectal Cancer

Alex Biese
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.